Media about us

  • 23 October 2017

    Contract R&D market is developing in Russia

    Contract R&D market is developing in Russia

    GMP News

    NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.

  • 23 October 2017

    Russian pharmaceutical map has a new point of convergence

    Russian pharmaceutical map has a new point of convergence

    GMP News

    An interesting international pharmaceutical project has started in Russia. This project is a result of a convergence of interests of Rusnano, Russian state investment corporation, Domain Associates, an American venture capital foundation, and Pfizer, an American pharmaceutical corporation.  

  • 20 October 2017

    NovaMedica receives a license for production site at its R&D center

    NovaMedica receives a license for production site at its R&D center

    GMP News

    NovaMedica received a license from the FBI SID & GP for a pilot production site at its R&D center. This was announced by Alexander Kuzin, the General Director of the company.

  • 08 September 2017

    New 30-minute STI test allows just one clinic trip

    New 30-minute STI test allows just one clinic trip

    Helen Clark / Gears of Biz

    A new speedy test will mean that for the first time ever patients with common sexually-transmitted infections will be able to get their diagnosis and treatment in one clinical visit. The test works by placing a swab or a small amount of urine into a test cartridge, which is then inserted into the diagnostic machine, which has been designed by innovation firm Atlas Genetics Ltd.

  • 07 September 2017

    Roche to up Russian Gazyva supply through local fill/finish deal

    Roche to up Russian Gazyva supply through local fill/finish deal

    Dan Stanton / BioPharma Reporter.com

    Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa. The policy has driven most multinationals to sign contracts with domestic drugmakers and invest in local joint ventures. Pfizer broke ground on a facility with NovaMedica in Kaluga in May, GSK formed a JV with Binnopharm in 2011, while AstraZeneca , Novartis and Novo Nordisk have all invested in Russian production facilities.

  • 17 August 2017

    Prostate Cancer: Epic Sciences AR-V7 Test

    Prostate Cancer: Epic Sciences AR-V7 Test

    OncLive

    Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.

  • 29 June 2017

    Syndax Locks In To Tumor Escape

    Syndax Locks In To Tumor Escape

    Seeking Alpha

    Syndax (NASDAQ:SNDX) is a $315 million market cap company focused on developing a pipeline of innovative combination therapies for cancer. The company's lead product is Entinostat, which was granted Breakthrough Therapy Designation by FDA for its Phase 2b clinical trial in advanced hormone receptor positive (Estrogen Receptor positive, ER+) breast cancer. The impact of Breakthrough Therapy Designation on biotechnology stocks has been previously described here by Strong Bio and is worth a read. The company has a host of impressive partnerships for its clinical trials, including Merck (NYSE:MRK) for a combinatory non-small cell lung cancer (NSCLC) and melanoma therapy, Genentech/Roche (OTCQX:RHHBY) for triple-negative breast cancer (TNBC), and Pfizer (NYSE:PFE) and Merck in Germany for ovarian cancer.

  • 16 June 2017

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed Researcher, Dr. Jack Edwards, Honored for Contributions to Medicine

    LA BioMed

    The Medical Mycology Society of the Americas has honored John E. “Jack” Edwards, Jr., MD, an LA BioMed lead researcher, as the winner of the 2017 Rhoda Benham Award. The award is given “to an individual from the Americas for continuous outstanding or meritorious contributions to medical mycology,” which is the study of fungal diseases. Dr. Edwards, together with his group of colleagues, founded NovaDigm Therapeutics to translate the three decades of research into products that will prevent or treat serious infectious diseases. 

  • 15 June 2017

    OD reports practices success with corneal inlay

    OD reports practices success with corneal inlay

    Jeffrey M. Augustine, OD / Healio

    The keys to success with the Raindrop Near Vision Inlay are patient selection and evaluation of ocular surface, centration and inflammation, he said. The use of corneal inlays for the surgical correction of presbyopia is an exciting new technology for optometry, ophthalmology and, especially, for the presbyopic patient.

  • 13 June 2017

    Pfizer eyes building another plant in Russia

    Pfizer eyes building another plant in Russia

    ThePharmaLetter

    US pharma giant Pfizer (NYSE: PFE) is considering building another manufacturing plant in Russia during the next several years, which is expected to be located in the Tatarstan Republic, one of Russia’s richest and economically developed regions. In addition on May 30, Pfizer officially started building its first Russian plant in the Kaluga Vorsino technopark, which takes place in cooperation with its local partner NovaMedica.

All Portfolio

MEDIA CENTER

  • NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    NovaMedica began construction of a pharmaceutical plant in the Kaluga region

    Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.

All news